Related references
Note: Only part of the references are listed.Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
Sven-Eric Olsson et al.
PAPILLOMAVIRUS RESEARCH (2020)
The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus
Elisabeth McClymont et al.
CLINICAL INFECTIOUS DISEASES (2019)
Trends and Characteristics Associated With Human Papillomavirus Vaccination Uptake Among Men Who Have Sex With Men in the United States, 2014-2017
Caitlin Loretan et al.
SEXUALLY TRANSMITTED DISEASES (2019)
The Accuracy of Anal Swab-Based Tests to Detect High-Grade Anal Intraepithelial Neoplasia in HIV-Infected Patients: A Systematic Review and Meta-analysis
Fernando Dias Goncalves Lima et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
Elissa Meites et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
Jessica A. Kahn et al.
PAPILLOMAVIRUS RESEARCH (2019)
Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States
Parag Mahale et al.
CLINICAL INFECTIOUS DISEASES (2018)
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298
Timothy J. Wilkin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Anal Cancer Risk Among People With HIV Infection in the United States
Vivian Colon-Lopez et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV
Jason Brophy et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2018)
delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men
G. B. Ellsworth et al.
PAPILLOMAVIRUS RESEARCH (2018)
Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1
Michelle S. Cespedes et al.
PAPILLOMAVIRUS RESEARCH (2018)
Human papillomavirus vaccination in men who have sex with men - what will be required by 2020 for the same dramatic changes seen in heterosexuals
Christopher K. Fairley et al.
SEXUAL HEALTH (2017)
Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine
Myron J. Levin et al.
VACCINE (2017)
Human Papillomavirus Vaccination Among Young Adult Gay and Bisexual Men in the United States
Paul L. Reiter et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2015)
Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women
Erna Milunka Kojic et al.
CLINICAL INFECTIOUS DISEASES (2014)
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study
Lynette Denny et al.
VACCINE (2013)
Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
Michael J. Silverberg et al.
CLINICAL INFECTIOUS DISEASES (2012)
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Joel M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old
Myron J. Levin et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men
Timothy Wilkin et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Elmar A. Joura et al.
LANCET (2007)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Share Paper
